HIMS Stock Falls -47% With A 10-day Losing Spree On FDA Crackdown
Hims & Hers Health (HIMS) – a telehealth platform offering consultations and wellness supplements – hit a 10-day losing streak, with cumulative losses over this period amounting to -47%. The company’s market cap has crashed by about $3.2 Bil over the last 10 days and currently stands at $3.6 Bil.
The stock has YTD (year-to-date) return of 51.3% compared to -0.2% for S&P 500. This calls for a re-evaluation of the stock’s valuation to find out whether this is an opportunity or a trap.
What Triggered The Slide?
[1] FDA Crackdown & HHS Referral to Dept of Justice
- Palantir At 80x Earnings: What Revenue Growth Rate Justifies The Valuation?
- Should You Pay Attention To Chevron Stock’s Momentum?
- What Is Happening With Caterpillar Stock?
- What Can Trigger Microsoft Stock’s Slide?
- Is Microsoft Stock A Trap Or A Missed Opportunity?
- Earn 9.6% Today or Buy BSX 30% Cheaper – It’s a Win-Win
- FDA announced GLP-1 restrictions
- HHS referred HIMS for potential violations
- Impact: Plunged 16% on Feb 9, Halted sales of compounded semaglutide
[2] Widespread Analyst Price Target Cuts
- BofA cut target to $21 with Underperform rating
- Canaccord Genuity slashed target to $30 from $68
- Impact: Accelerated stock decline, Reinforced negative institutional sentiment
Opportunity or Trap?
Below is our take on valuation.
There is not much to fear in HIMS stock given its overall Strong operating performance and financial condition. This is aligned with the stock’s High valuation because of which we think it is Fairly Priced (For details, see Buy or Sell HIMS).
But here is the real interesting point.
You are reading about this -47% move after it happened. The market has already priced in the news. To avoid the next loser before the headlines, you need predictive signals, not notifications. Our High Quality Portfolio has a risk model designed to reduce exposure to losers.
Returns vs S&P 500
The following table summarizes the return for HIMS stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | HIMS | S&P 500 |
|---|---|---|
| 1D | -5.3% | -1.6% |
| 10D (Current Streak) | -47.1% | -2.0% |
| 1M (21D) | -50.9% | -1.9% |
| 3M (63D) | -60.3% | -0.2% |
| YTD 2026 | -51.3% | -0.2% |
| 2025 | 34.3% | 16.4% |
| 2024 | 171.7% | 23.3% |
| 2023 | 38.8% | 24.2% |
Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: HIMS Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 74 S&P constituents with 3 days or more of consecutive gains and 77 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 35 | 40 |
| 4D | 14 | 31 |
| 5D | 14 | 2 |
| 6D | 7 | 2 |
| 7D or more | 4 | 2 |
| Total >=3 D | 74 | 77 |
Key Financials for Hims & Hers Health (HIMS)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $872.0 Mil | $1.5 Bil |
| Operating Income | $-29.5 Mil | $61.9 Mil |
| Net Income | $-23.5 Mil | $126.0 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $544.8 Mil | $599.0 Mil |
| Operating Income | $26.7 Mil | $11.8 Mil |
| Net Income | $42.5 Mil | $15.8 Mil |
The losing streak HIMS stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.